This photograph taken on October 30, 2022, shows the logo of the Swiss pharmaceutical and drug maker Novartis on a building in Basel."We are driven by science and the technology, in this case this was a perfect fit for us … If you take a look at our free cash flow it approaching $20 billion a year, so we have adequate firepower to do deals like this and to bolster the growth profile of the company," Narasimhan told CNBC's "Europe Early Edition."The purchase will give the Basel, Switzerland-based pharma gian ...